Johnson & Johnson (NYSE:JNJ) is one of the 10 Unrivaled Stocks of the Next 3 Years. On September 3, Wolfe Research increased the price target for Johnson & Johnson (NYSE:JNJ) from $175 to$195 and kept an Outperform rating. Wolfe Research cited growing confidence in Johnson & Johnson’s (NYSE:JNJ) upcoming talc litigation outcome. This confidence led the firm to use lower weighted average cost of capital (WACC) assumptions in its discounted cash flow analysis. Wolfe Research Lifts PT for Johnson & Johnson ...